Jump to main content
Jump to site search

Issue 43, 2019
Previous Article Next Article

A spermine-conjugated lipophilic Pt(IV) prodrug designed to eliminate cancer stem cells in ovarian cancer

Author affiliations

Abstract

We developed a spermine-conjugated lipophilic Pt(IV) prodrug that is able to reduce the cancer stem cell population in ovarian cancer. The therapeutic effect is attributed to the hydrophobic tail and cationic spermine head group, the combination of which allows the Pt(IV) prodrug to localize in mitochondria and induce corresponding damage.

Graphical abstract: A spermine-conjugated lipophilic Pt(iv) prodrug designed to eliminate cancer stem cells in ovarian cancer

Back to tab navigation

Supplementary files

Publication details

The article was received on 14 Mar 2019, accepted on 26 Apr 2019 and first published on 01 May 2019


Article type: Communication
DOI: 10.1039/C9CC02081K
Chem. Commun., 2019,55, 6106-6109

  •   Request permissions

    A spermine-conjugated lipophilic Pt(IV) prodrug designed to eliminate cancer stem cells in ovarian cancer

    M. Stilgenbauer, A. M. D. S. Jayawardhana, P. Datta, Z. Yue, M. Gray, F. Nielsen, D. J. Bowers, H. Xiao and Y. Zheng, Chem. Commun., 2019, 55, 6106
    DOI: 10.1039/C9CC02081K

Search articles by author

Spotlight

Advertisements